Viravaxx AG

An Austrian research company dedicated to the development of immune diagnostics and vaccines

Viravaxx develops multiplexed tools for high resolution serum immune diagnostics based on microarray technology. Our technology enables high resolution mapping and identification of epitopes which elicit an immune response following infections of the respiratory tract.

Viravaxx’ vaccine program is based on proprietary peptide carrier technology. We have developed vaccine candidates against hard-to-treat viral diseases, such as infections with hepatitis B virus, respiratory syncytial virus and rhinovirus. Notably, we have also developed a potent SARS-CoV-2 vaccine candidate.

Viravaxx has a dedicated team of 10 scientists and technicians in cooperation with the Valenta Labs at the Medical University of Vienna. Viravaxx’ lead product is a clinical Ph 2 hepatitis B vaccine candidate for therapeutic and prophylactic vaccination.

Our company’s technology platform and our advances in designing potent vaccine candidates have raised attention within the worldwide scientific community. Exemplary, India’s well known online journal Future Medicine has recently conducted the following interview with Viravaxx:

 

Future Medicine India

Online version of full article here 

Future-Medicine-India_E_0206_06